Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.32 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9077277 | 0.96 | L3MBTL1 (0.47) | L3MBTL1KMT2AHAVCR2PTK2TSHR | |
| SCHEMBL8265453 | 0.76 | ALDH1A1 (0.41) | L3MBTL1KMT2AHAVCR2KDM4ECYP1A2 | |
| SCHEMBL2502652 | 0.76 | L3MBTL1 (0.47) | L3MBTL1KMT2APTK2TSHRKDM4E | |
| SCHEMBL21663010 | 0.76 | L3MBTL1 (0.47) | L3MBTL1KMT2APTK2TSHRPKN1 | |
| SCHEMBL2475108 | 0.76 | L3MBTL1 (0.47) | L3MBTL1KMT2APTK2TSHRPKN1 | |
| SCHEMBL2513496 | 0.72 | L3MBTL1 (0.44) | L3MBTL1KMT2ATSHRMAPTLMNA | |
| SCHEMBL2510671 | 0.72 | KMT2A (0.44) | L3MBTL1KMT2ATSHRKDM4E | |
| SCHEMBL2756447 | 0.70 | — | — | |
| SCHEMBL4773286 | 0.69 | KMT2A (0.42) | L3MBTL1KMT2AKDM4EHIF1AALDH1A1 | |
| SCHEMBL19153079 | 0.68 | KDM4E (0.43) | KMT2AHAVCR2TSHRKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168088-B2 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. | 2021-11-09 | — | — | US | disclosed |
| US-20200039983-A1 | PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-02-06 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20070244173-A1 | 6,7-Dihydroxy-8-Phenyl-3,6,7,8-Tetrahydro-Chromeno [7,8-d] Imidazole Derivatives and Their Use as Gastric Acid Secretion Inhibitors | ALTANA PHARMA AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070037840-A1 | Tricyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-02-15 | — | — | US | disclosed |
| EP-1742951-A1 | 6,7-DIHYDROXY-8-PHENYL-3,6,7,8-TETRAHYDRO-CHROMENO[7, 8-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS | Altana Pharma AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1697357-A2 | TRICYCLIC BENZIMIDAZOLES | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005103057-A1 | 6,7-DIHYDROXY-8-PHENYL-3,6,7,8-TETRAHYDRO-CHROMENO[7, 8-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005058893-A1 | TRICYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | L3MBTL1 669/4885KMT2A 1005/4885HAVCR2 382/4885 |
| US-20070244173-A1 | 6,7-Dihydroxy-8-Phenyl-3,6,7,8-Tetrahydro-Chromeno [7,8-d] Imidazole Derivatives and Their Use as Gastric Acid Secretion Inhibitors | GIPR, CYP7A1, PGC | L3MBTL1 4735/4885KMT2A 3899/4885HAVCR2 4379/4885 |
| US-20070037840-A1 | Tricyclic benzimidazoles | VIP, GIPR, PGC | L3MBTL1 2465/4885KMT2A 3413/4885HAVCR2 4549/4885 |
| US-11168088-B2 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | CYP2D6, PNPO, CYP2B6 | L3MBTL1 4827/4885KMT2A 2962/4885HAVCR2 3247/4885 |
| US-20200039983-A1 | PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | CYP2D6, PNPO, CYP2B6 | L3MBTL1 4827/4885KMT2A 2962/4885HAVCR2 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.